

Find out what you can do.



Breaking News

- Email
- Print
- Share

Jul 3 2008, 11:45 AM EST

Stem cells from umbilical cord used in the treatment of hepatic diseases

EUREKALERT

Contact: Dr. Luis Fontana Gallego fontana@ugr.es 34-958-242-335 Universidad de Granada

This release is available in **Spanish**.

Scientists of the University of Granada, in collaboration with the University of Len, have confirmed that stem cells from human umbilical cord blood can be an appropriate therapy for the treatment of hepatic diseases such as hepatitis, and therefore mean an effective alternative to bone marrow. According to a scientific paper which will be shortly published in the renowned journal *Cell Transplantation*, human umbilical cord blood cells (HUCBCs) can be useful for hepatic regenerative medicine, as they can nest in the liver after carrying out a human-to-rat xenotransplant.

This work, carried out by Ana I. lvarez-Mercado, Mara J. Sez-Lara, Mara V. Garca-Mediavilla, Sonia Snchez-Campos, Francisco Abada, Mara Cabello-Donayre, ngel Gil, Javier Gonzlez-Gallego and Luis Fontana, did research into the regenerative potential of HUCBCs cells using a xenotransplant model from human to rat in which HUCBCs were injected through the hepatic portal vein of rats with hepatitis caused by D-galactosamine.

Successfully in rats

The scientists explain that the cell transplant carried out in rats caused an improvement both in the histological damage and in the hepatic function, as proved by the enzymatic activities of alanine transaminase, alkaline phosphatase, gama-glutamyl-transpherase and lactate dehydrogenase, as well as the concentrations of total and direct bilirubin. The present treatment for terminal hepatic failure consists of a liver transplant. This method is, however, limited due to the lack of donor organs. In addition, there is not at present a specific treatment for the fibrosis caused by many hepatic diseases, so that receive a treatment for the complications of the disease. The development of such alternatives is therefore an essential objective for present research to improve suffering in many patients.

###

04/07/2008 11:45

Note: video in http://es.youtube.com/watch?v=uEzdKwym3CI

TV quality video (in Spanish): http://prensa.ugr.es/prensa/campus/peticion.php?nota=4633

- Print
- **■** Share

PODCASTS

- Listen
- Save
 Comment
 View All

INTERVIEW: NEW INITIATIVE FOR MAPPING ALL CELL TYPES DERIVED FROM HUMAN EMBRYONIC STEM CELLS --- Interview with Michael West, Ph.D., Chief Executive Officer, BioTime, Inc. ...more



ADVERTISEMENT



MOST POPULAR

<u>▼News</u>

Most Viewed Most Emailed Top Searches

FDA Hits Merck & Co. with Double Whammy for Gardasil Label Extensions

PPD Expands Eastern European Presence

Vaccine Containing Tumor Antigen Reduces Colon Cancer Spread in Mice

Stiefel Laboratories to Take Over Barrier Therapeutics for \$148M

Merck & Co. to Pay Schering-Plough \$105M with Decision to Pull the Plug on Respiratory JV

Novo Nordisk to Pay \$87M for Emisphere's Drug Delivery Technology

 $\underline{Axentis\ Pharma\ Gains\ Patents\ from\ BioDevelops\ Pharma\ to\ Further\ Cystic\ Fibrosis\ Program}$

Researchers Find that Human Cells Can Move tRNAs into Their Mitochondria

<u>Intas Biopharmaceuticals Acquires Biologics Process Development</u>

SNPs in IL2RA Gene Linked to Juvenile Idiopathic Arthritis

Articles

Blogs

back to top | HOME | SUBSCRIBE

© 2008 Genetic Engineering & Biotechnology News, All Rights Reserved - $\underline{\text{terms of use}} \mid \underline{\text{legal}}$ information | privacy statement | contact | about GEN | SITE MAP

04/07/2008 11:45 3 de 3